Table 2.
In vitro susceptibility of representative baseline CRAB isolates from eight patients
| Patient-isolate | MIC (mg/L) | Fractional inhibitory concentration (interpretation) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDC | ERV | TGC | MIN | MEM | PMB | SUL | MEM + MIN | MEM + PMB | MEM + SUL | MIN + PMB | MIN + SUL | PMB + SUL | |
| BCU1-1 | 0.25 | 0.5 | 1 | 4 | >64 | ≤0.25 | 16 | 1.5 (I) | 2 (I) | 1 (I) | 2 (I) | 1 (I) | 1 (I) |
| MICU13-1 | 0.12 | 0.5 | 1 | 4 | >64 | ≤0.25 | 16 | 0.375 (S) | 2 (I) | 1.5 (I) | 2 (I) | 1 (I) | 1 (I) |
| BCU4-0 | 0.12 | 0.5 | 1 | 4 | >64 | 0.5 | 16 | 1.5 (I) | 1.5 (I) | 0.625 (A) | 0.501 (A) | 1 (I) | 0.625 (A) |
| MICU10-1 | 0.25 | 0.5 | 1 | 4 | >64 | 0.5 | 16 | 1.5 (I) | 1.5 (I) | 1.5 (I) | 2 (I) | 2 (I) | 1 (I) |
| BCU9-1 | 0.12 | 0.5 | 1 | 4 | >64 | 0.5 | 16 | 1.5 (I) | 2 (I) | 0.625 (A) | 0.565 (A) | 2 (I) | 1 (I) |
| MICU-12-1 | 0.25 | 0.5 | 1 | 8 | >64 | ≤0.25 | 8 | 1 (I) | 2 (I) | 1.25 (I) | 2 (I) | 1 (I) | 0.75 (A) |
| MICU7-1 | 0.12 | 0.5 | 2 | 4 | >64 | ≤0.25 | 8 | 1.5 (I) | 2 (I) | 2 (I) | 2 (I) | 1 (I) | 0.625 (A) |
| MICU11-0 | 0.12 | 0.5 | 2 | 4 | >64 | 0.5 | 8 | 1.5 (I) | 2 (I) | 1.5 (I) | 1.5 (I) | 1.5 (I) | 0.56 (A) |
FDC, Cefiderocol; ERV, Eravacycline; TGC, Tigecycline; MIN, Minocycline; MEM, Meropenem; PMB, Polymyxin B; SUL, Sulbactam.
Note. The following criteria was used to interpret fractional inhibitory concentration values: <0.5 = Synergy (S), 0.5–1 = Additive (A), >1 = Indifferent (I).